Mohammad AskarPublic working copy · medical review pending

Long-acting anti-VEGF treatment · 139

Long-acting anti-VEGF: match the evidence to the disease

Reduce treatment burden through response-guided intervals while keeping function, safety and follow-up in view.

Public working copy · medical review pending. Source, translation and medical checks remain open. Read the limitations in the text and references. These educational materials do not replace individual medical assessment. Published: 2026-11-18T19:45:52+01:00. Internal project references lead to this notice. They are not publicly accessible primary sources; the source limitations remain stated in the text.

PULSAR supports selected aflibercept 8 mg regimens in naive nAMD; DME and RVO require their own studies and labels. Longer intervals are not unmonitored pauses, and similar mean vision does not prove identical safety.

Terminology and draft status

Terminology review is not complete. Selected actual WHO UMD queries and their limits are recorded in terminology.md; they do not approve the whole translation.

01Start with disease activity and the patient’s burden

VEGF-mediated permeability and abnormal vessel growth contribute to nAMD, diabetic macular oedema (DME) and RVO-related oedema, but their mechanisms and trial populations differ. Inflammation and barrier failure interact; not every eye has the same sequence or neovascularisation. Regular injections, travel and carers’ time can be burdensome; discuss actual barriers rather than assuming that fewer injections automatically improve adherence or quality of life. 1

Assess acuity, OCT fluid and central thickness, haemorrhage and adverse effects after initiation and during maintenance. Persistent spaces may represent active exudation, degenerative cavities, traction or segmentation artefact. A dry early scan may be associated with longer intervals but is not a validated individual prediction or assurance against later reactivation. 1

02Distinguish dose rationale from PULSAR evidence

Higher starting molar concentration may keep a drug above an activity threshold for longer, but a decay model does not prescribe an injection interval. Aflibercept 8 mg is 4 times the 2 mg dose; duration, benefit and safety must still be demonstrated clinically. PULSAR randomised 1011 naive nAMD adults, of whom 1009 were treated; following 3 monthly doses, 8 mg every 12 or 16 weeks was compared with 2 mg every 8 weeks, with protocol-guided adjustment. 1 2

At week 48, mean gains were 6.7/6.2/7.6 letters for 8q12/8q16/2q8. Adjusted differences versus 2q8 were −0.97 (95% CI −2.87 to 0.92) and −1.14 (−2.97 to 0.69), meeting the 4-letter non-inferiority margin. Randomisation and double masking support this comparison; Bayer/Regeneron funding, missing follow-up, selected eligibility and the fixed comparator limit wider conclusions. Non-inferiority is not superior vision or exact equality. 2

At week 96, 869 completed treatment: modelled vision gains were 5.6/5.5/6.6 letters and completer injections 9.7/8.2/12.8. Among completers, last assigned intervals reached ≥12 weeks in 87% of 8q12 and ≥16/≥20/24 weeks in 78%/53%/31% of 8q16. Last assignment, maintained interval and modelled versus completer denominators differ. Anatomical drying and fewer injections do not alone prove improved daily function, adherence or equal rare-event safety. 3

03Read faricimab and DME evidence separately

Faricimab targets VEGF-A and Ang-2. TENAYA/LUCERNE randomised 1329 naive nAMD participants to selected 6 mg faricimab intervals up to 16 weeks or aflibercept 2 mg every 8 weeks. At 1 year, gains were 5.8 versus 5.1 and 6.6 versus 6.6 letters, meeting a 4-letter non-inferiority margin. These Roche-funded masked trials support their selected schedules, not superiority to all flexible agents or to aflibercept 8 mg. 4 9

Of 1326 treated TENAYA/LUCERNE participants, 1113 (83.9%) completed 2 years. At week 112, faricimab every 16 weeks was assigned to 59%/66.9% and at least every 12 weeks to 74.1%/81.2%. Mean gains were 3.7 versus 3.3 and 5.0 versus 5.2 letters; attrition, protocol criteria and the distinction between assigned dosing and every patient’s actual course matter. Absence of a safety difference does not establish equal rare risks. 5

PHOTON is a separate randomised DME trial: 660 randomised, 658 treated. At week 48, 8q12/8q16/2q8 gains were 8.8/7.9/9.2 letters; adjusted differences −0.57 (95% CI −2.26 to 1.13) and −1.44 (−3.27 to 0.39) met a 4-letter margin. At week 96, 534 completed, gains were 8.8/7.5/8.4 and completer injections 9.5/7.8/13.8. This Regeneron/Bayer-funded trial does not transfer its DME outcome or selected extensions to every nAMD/RVO eye. 6 7

04Match current EU indications and drug-specific safety

Current EU Eylea 114.3 mg/mL information lists adult nAMD, DME and RVO-related oedema: 8 mg uses 0.07 mL. For initiating nAMD/DME, 3 monthly doses may be followed by response-guided extension up to 4 months, then potentially up to 6 months with stable outcomes. Stable switch patients may retain/extend after the first dose, while suboptimal response may need up to 3 monthly doses. RVO has its own schedule; check the current indication and response rather than applying one loading or extension rule to all agents. 8

Faricimab is authorised in the EU for adult nAMD, DME and RVO-related macular oedema, with indication-specific assessment; shared biology is not permission to reuse PULSAR intervals. Brolucizumab has a recognised intraocular-inflammation, retinal-vasculitis and retinal-vascular-occlusion concern. Across agents, monitor infection, pressure, inflammatory and systemic vascular risks; mean trial safety and a larger injection volume are not guarantees of equal or absent harm. 8 9 10

05Distinguish an implant from a longer injection interval

The ranibizumab port-delivery approach now has an EU authorisation: Susvimo was approved on 18 September 2026 for adult nAMD stable after responding to prior intravitreal anti-VEGF. The historical 2023 withdrawn application is not current EU non-approval. Susvimo 100 mg/mL is for the Contivue implant only, not substitution for ordinary ranibizumab bolus injection; refill-exchange is every 24 weeks, approximately 6 months. This indication does not automatically include naive nAMD, DME or RVO. 11

Implant insertion/removal requires a trained vitreoretinal surgeon and operating-room conditions; refill-exchange requires trained aseptic care. Monitoring and occasional supplemental intravitreal treatment may still be needed. Implant risks include vitreous haemorrhage, conjunctival leak/erosion/retraction, endophthalmitis, retinal tear/detachment and septum or implant displacement; some are asymptomatic. Current manufacturer instructions, tissue examination and counselling remain essential, so fewer refills are not equivalent to fewer visits or risk-free care. 11

06Agree an individual treat-and-extend plan

Select 2 mg, 8 mg or another treatment according to cause, response, licensed indication, risks, availability and preference. With controlled activity, extend gradually within the relevant schedule; with new activity, shorten or reconsider the diagnosis/treatment. Document the finding, rationale, achieved interval and next assessment. Continued treatment without benefit is not justified merely because stopping can risk recurrence. 1

Teach the warning symptoms and agree what to do if a visit is missed. A long interval is a planned monitored strategy, not permission to omit treatment independently. Review realistic visual goals, travel and carer needs, and distinguish a study finding from current product information, local guidance or reimbursement rules. 1

What are the main learning points?

PULSAR supports selected aflibercept 8 mg regimens in naive nAMD; DME and RVO require their own studies and labels. Longer intervals are not unmonitored pauses, and similar mean vision does not prove identical safety.

When is assessment urgent?

New distortion, rapid visual loss, fresh haemorrhage or worsening fluid needs prompt reassessment. Severe pain, marked redness, photophobia or visual deterioration after injection needs immediate eye-emergency assessment. Do not extend or omit treatment independently. Rapid visual loss, severe pain, marked inflammation, a pressure rise or suspected infection or neurological disease also needs urgent assessment.

References and access status

  1. 1
    Immutable original export; own long-acting anti-VEGF summary; clinical inventory matches the other summary but wrapper identity retained

    Complete export read; original attribution and any recording/transcript or appointment not independently verified.

  2. 2
    PULSAR 48 weeks, 2024

    Complete primary NCBI abstract independently read 15 November 2026; full report, protocol, figures and supplements unread.

  3. 3
    PULSAR 96 weeks, 2026

    Complete primary NCBI abstract independently read 15 November 2026; full report, protocol, figures and supplements unread.

  4. 4
    TENAYA/LUCERNE 1 year, 2022

    Complete primary NCBI abstract independently read 15 November 2026; full report, protocol, figures and supplements unread.

  5. 5
    TENAYA/LUCERNE 2 years, 2024

    Complete primary NCBI abstract independently read 15 November 2026; full report, protocol, figures and supplements unread.

  6. 6
    PHOTON 48 weeks, 2024

    Complete primary NCBI abstract independently read 15 November 2026; full report, protocol, figures and supplements unread.

  7. 7
    PHOTON 96 weeks, 2026

    Complete primary NCBI abstract independently read 15 November 2026; full report, protocol, figures and supplements unread.

  8. 8
    EMA Eylea: current selected EU 8 mg product information

    Actual downloaded PDF selected pages 64–67, sections 4.1–4.4 read 15 November 2026; not complete label or reimbursement review.

  9. 9
    EMA Vabysmo: current overview

    Official indication/mechanism/benefit/risk overview read 15 November 2026; not full product information or full RVO/DME trial appraisal.

  10. 10
    EMA Beovu: inflammatory and occlusive vascular risks

    Official overview and indexed EMA safety communication read 15 November 2026; no complete current SmPC or individual risk prediction.

  11. 11
    EMA Susvimo: EU approval 18 September 2026 and current product information

    Actual official downloaded SmPC selected pages 2–6, sections 4.1–4.4 read 15 November 2026, plus EMA approval overview. Not full SmPC, manufacturer IFU or full implant-trial appraisal. The 2023 withdrawn application is historical, not current EU status.